Literature DB >> 10413389

Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers.

P J Neumann1, K M Kuntz, J Leon, S S Araki, R C Hermann, M A Hsu, M C Weinstein.   

Abstract

OBJECTIVES: Although the broad impacts of Alzheimer's disease (AD) are increasingly recognized, little work has focused on the overall health-related quality of life experienced by Alzheimer's disease patients and their caregivers. The study had two main objectives: (1) to test the feasibility of measuring health utilities in Alzheimer's disease with a generic preference-weighted instrument using proxy respondents and (2) to assess the utility scores of Alzheimer's disease patients (and their caregivers) in different disease stages and care setting.
METHODS: A cross-sectional study of 679 Alzheimer's disease patient/caregiver pairs was conducted at 13 sites in the United States: four academic medical centers, four managed care plans, two assisted living facilities, and three nursing homes. The Health Utilities Index Mark II (HUI:2) questionnaire was administered to caregivers of patients who responded both as proxies for patients and for themselves. Responses to the questionnaire were converted into a global utility score, between 0 and 1, using the HUI:2 multi-attribute utility function.
RESULTS: Global utility scores varied considerably across patients' Alzheimer's disease stage: for the six stages assessed (questionable, mild, moderate, severe, profound, and terminal), mean utility scores were 0.73, 0.69, 0.53, 0.38, 0.27, and 0.14, respectively. In multiple regression analyses, Alzheimer's disease stage was a negative and significant predictor of utility scores for patients; setting did not exert an independent effect. Utility scores for the caregivers were insensitive to patients' Alzheimer's disease stage and setting.
CONCLUSIONS: Patients' Alzheimer's disease stage had a substantial influence on health utilities, as measured by the HUI:2. More research is needed to assess the validity of using proxy respondents.

Entities:  

Mesh:

Year:  1999        PMID: 10413389     DOI: 10.1097/00005650-199901000-00005

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  49 in total

1.  Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication.

Authors:  J L Bosch; M G Hunink
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Authors:  Jaime Caro; Maribel Salas; Alexandra Ward; Denis Getsios; Kristen Migliaccio-Walle; Frances Garfield
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

3.  Health utility elicitation: is there still a role for direct methods?

Authors:  Lisa A Prosser; Scott D Grosse; Eve Wittenberg
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

Review 4.  Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives.

Authors:  A Simon Pickard; Sara J Knight
Journal:  Med Care       Date:  2005-05       Impact factor: 2.983

Review 5.  A review of quality of life instruments used in dementia.

Authors:  Teake P Ettema; Rose-Marie Dröes; Jacomine de Lange; Gideon J Mellenbergh; Miel W Ribbe
Journal:  Qual Life Res       Date:  2005-04       Impact factor: 4.147

6.  Utility-based Quality of Life measures in Alzheimer's disease.

Authors:  Gary Naglie; George Tomlinson; Catherine Tansey; Jane Irvine; Paul Ritvo; Sandra E Black; Morris Freedman; Michel Silberfeld; Murray Krahn
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

Review 7.  Role of cholinesterase inhibitors in dementia care needs rethinking.

Authors:  Anthony J Pelosi; Seamus V McNulty; Graham A Jackson
Journal:  BMJ       Date:  2006-09-02

8.  Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.

Authors:  Stefan J Teipel; Michael Ewers; Veronika Reisig; Bernd Schweikert; Harald Hampel; Michael Happich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-04-01       Impact factor: 5.270

9.  Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis.

Authors:  Peter J Neumann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 10.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.